EP Patent

EP1429731B1 — Nanoparticulate insulin formulations

Assigned to Perrigo Pharma International DAC · Expires 2007-01-03 · 19y expired

What this patent protects

Nanoparticulate insulin compositions having effective an average particle size of less than about 5 microns are described. The compositions exhibit retention of insulin bioactivity, increased bioavailability, and increased consistency of bioavailability as compared to prior macro…

USPTO Abstract

Nanoparticulate insulin compositions having effective an average particle size of less than about 5 microns are described. The compositions exhibit retention of insulin bioactivity, increased bioavailability, and increased consistency of bioavailability as compared to prior macro-sized insulin compositions. Methods of making nanoparticulate insulin compositions, dosage forms containing them, and the use of such formulations in insulin therapy are also described.

Drugs covered by this patent

Patent Metadata

Patent number
EP1429731B1
Jurisdiction
EP
Classification
—
Expires
2007-01-03
Drug substance claim
No
Drug product claim
No
Assignee
Perrigo Pharma International DAC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.